Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort

Considerable concern has emerged for the potential harm in the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor inhibitors (ARBs) in COVID-19 patients, given that ACEIs and ARBs may increase the expression of ACE2 receptors that represent the way for coronavirus 2 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Anzola, Gian Paolo, Bartolaminelli, Clara, Gregorini, Gina Alessandra, Coazzoli, Chiara, Gatti, Francesca, Mora, Alessandra, Charalampakis, Dimitrios, Palmigiano, Andrea, De Simone, Michele, Comini, Alice, Dellaglio, Erica, Cassetti, Salvatore, Chiesa, Maurizio, Spedini, Francesca, d’Ottavi, Patrizia, Savio, Maria Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Im - Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508677/
https://www.ncbi.nlm.nih.gov/pubmed/32965603
http://dx.doi.org/10.1007/s11739-020-02500-2

Ejemplares similares

Ejemplares similares